Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenolol for Prevention of Postmenopausal Bone Loss
NCT04905277Phase 2Completed
- Start
- Jul 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoporosis comparing Atenolol with Placebo (2 arms). Primary endpoint: Percent change in total hip bone mineral density at 24 months. Started Jul 2021; status: completed.
02
Drugs
atenolol
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04905277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905277.